Factors determining successful allogeneic hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes
Open Access
- 30 June 2026
- journal article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (2) , 25-36
Abstract
Introduction. Inherited bone marrow failure syndromes (IBMFS) constitute a heterogeneous group of rare genetic disorders associated with impaired hematopoiesis, congenital anomalies, and a high risk of transformation to myelodysplastic syndrome and acute myeloid leukemia. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for IBMFS. Aim: to identify factors determining the efficacy of allo-HSCT in pediatric patients with IBMFS. Materials and methods. This study analyzed data from 61 patients with IBMFS who had undergone allo-HSCT between 2005 and 2025 at the R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation. Results. The median follow-up was 24 months. The overall survival (OS) at 1, 3, and 5 years post-transplantation was 88%, 85%, and 81%, respectively. The lowest 5-year OS was observed in the Fanconi anemia (47%) and Diamond–Blackfan anemia (86%) groups, whereas in the patients with other IBMFS the 5-year OS reached 100% (p = 0.003). Factors associated with improved survival included age younger than 5 years at transplantation (100% vs. 68%; p = 0.009), the use of myeloablative conditioning regimens (100% vs. 64.5%; p = 0.002), the use of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis (100% vs. 67%; p = 0.02), and successful engraftment (88% vs. 33%; p = 0.002). GVHD prophylaxis regimens without calcineurin inhibitors were associated with a lower incidence of grade II–IV acute GVHD (11% vs. 44%; p = 0.03) and a reduced need for switching immunosuppression (5% vs. 35%; p = 0.02). Donor type and degree of HLA matching did not significantly affect survival. Conclusion. Allo-HSCT is a highly effective treatment for children with IBMFS, providing a 5-year OS of 81%. The best outcomes are achieved with allo-HSCT performed at an early age (under 5 years), the use of myeloablative conditioning regimens (when not contraindicated), and with the addition of PTCy to GVHD prophylaxis. The lowest survival was observed in the patients with Fanconi anemia, highlighting the need for further refinement of treatment protocols for this patient group. PTCy-based GVHD prophylaxis regimens without calcineurin inhibitors reduce the incidence of acute GVHD and improve the tolerability of immunosuppression.Keywords
This publication has 30 references indexed in Scilit:
- Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTRTransplantation and Cellular Therapy, 2025
- Outcomes of allogeneic hematopoietic stem cell transplantation in Shwachman-Diamond syndrome: a systematic review and meta-analysisCytotherapy, 2024
- Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experienceBone Marrow Transplantation, 2024
- HLA‐haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working partiesAmerican Journal of Hematology, 2024
- The EBMT Handbook2024
- Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromesInternational Journal of Hematology, 2022
- Haplo‐identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMTAmerican Journal of Hematology, 2021
- Outcome of hematopoietic stem cell transplantation (HCT) from HLA-matched related donor for Fanconi anemia (FA) in adolescents and adults: a retrospective study by Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT)Bone Marrow Transplantation, 2020
- Natural history of human papillomavirus and vaccinations in men: A literature reviewHealth Science Reports, 2019
- Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic AnemiaTransplantation and Cellular Therapy, 2018